Vimarsana
Biggest News Aggregation in the World

Page 5 - Chronic Sinusitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chronic Sinusitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chronic Sinusitis Today - Breaking & Trending Today

BOLD CAPITAL ENTERPRISES LTD. PROVIDES UPDATE ON PROPOSED ACQUISITION OF SINUSAFE MEDICAL LTD. - Vimarsana News

BOLD CAPITAL ENTERPRISES LTD. PROVIDES UPDATE ON PROPOSED ACQUISITION OF SINUSAFE MEDICAL LTD.

/CNW/ - Bold Capital Enterprises Ltd. ("Bold") (TSXV: BOLD.P) is pleased to provide shareholders with an update with respect to its previously announced (see...

Sinus Therapeutic Drugs Market Expected to Grow at a CAGR of 6.3% Between 2020 and 2030 - Vimarsana News

Sinus Therapeutic Drugs Market Expected to Grow at a CAGR of 6.3% Between 2020 and 2030

The global sinus therapeutic drugs market will reach US$ 4.29 Bn by 2030, growing at a steady CAGR during 2020-2030, according to a research conducted by ESOMAR-certified firm, Future Market Insights (FMI)The development of biologics is amongst the most important factors catalysing the sinus therapeutic drugs market...

United States Drug Eluting Sinus Stent (DESS) Market Report 2022-2025 with Profiles of Intersect ENT, Medtronic plc, Stryker Corp (Entellus Medical, Inc.), and Johnson & Johnson - Vimarsana News

United States Drug Eluting Sinus Stent (DESS) Market Report 2022-2025 with Profiles of Intersect ENT, Medtronic plc, Stryker Corp (Entellus Medical, Inc.), and Johnson & Johnson

/PRNewswire/ -- The "The US Drug Eluting Sinus Stent (DESS) Market: Analysis By Procedures (Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus...

Nasal Microbiota Show Promise as Polyp Predictor - Vimarsana News

Nasal Microbiota Show Promise as Polyp Predictor

Distinct nasal microbiota associated with rhinosinusitis may yield a tool for predicting rhinosinusitis recurrence after sinus surgery.

Clinical Data Affirms Dupilumab for Chronic Nasal Polyps - Vimarsana News

Clinical Data Affirms Dupilumab for Chronic Nasal Polyps

Provisional 'real-life' data showed dupilumab improved outcomes for challenging patients with chronic rhinosinusitis and nasal polyps.